CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET.
The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events page. A replay of the webcast will be available after the event.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
New partnership empowers employees to use pre-tax dollars for functional medicine and health interventions, while…
ORLANDO, Fla., Jan. 13, 2026 /PRNewswire/ -- Smart Alert Tech today announces a groundbreaking advancement…
OMAHA, Neb., Jan. 13, 2026 /PRNewswire/ -- Medical Solutions, one of the nation's leading healthcare…
SAN FRANCISCO, Jan. 13, 2026 /PRNewswire/ -- Manifold Health AI today announced its launch at JPM…
(CSE: URAI / OTC: URAIF / FSE: 3QG) investor@inturai.comHighlightsU.S. OTC trading code has changed to URAIF, reflecting…
Marvin's role-specific AI coaches will augment its 24/7 therapist network for its 100+ healthcare partners…